Since PPARα has hypolipidemic and PPARγ has insulin sensitizing properties, these transcription factors have been of large clinical interest as targets for medical treatment of conditions involving cardiovascular disease and diabetes [6, 7]. The gene discussed is PPARA; the disease is cardiovascular disorder.